Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lestaurtinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 10/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 1.00 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | MYLK | Q15746 | 4/20 | 1.00 |
| ▸ | CDK4 | P11802 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lestaurtinib SCHEMBL16139562 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL730955 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL12228516 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL29625224 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971367 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971365 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL12963759 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL13169434 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL30149252 | 0.99 | NTRK1 (0.98) | NTRK1KDRPRKCQFLT3PRKD3 | |
| SCHEMBL14342269 | 0.94 | NTRK1 (0.89) | NTRK1KDRPRKCQFLT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| CN-110882294-A | Pharmaceutical composition for relieving and/or treating inflammatory pain | 西安跃亿智产信息科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| EP-2635299-B1 | METHODS FOR TREATING HAIR LOSS DISORDERS | UNIV COLUMBIA (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12527818-B2 | Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (GR) binding agents, and/or HSP90 binding agents for uses in treating cancer | EMORY UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12391946-B2 | Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms | GERON CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250249112-A1 | MACROPINOCYTOSIS SELECTIVE NON-BINDING PROTEIN-DRUG CONJUGATES | TEZCAT BIOSCIENCES, INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2008013782-A2 | METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021013-A1 | JAK inhibitors for treatment of myeloproliferative disorders | CEPHALON, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021013-A1 | JAK inhibitors for treatment of myeloproliferative disorders | CEPHALON, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007075307-A2 | CRYSTALLINE LESTAURTINIB HYDRATES AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMIACETONITRILEATE AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMITETRAHYDROFURANATE | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007070444-A1 | LESTAURTINIB CRYSTALLINE FORM 1, CRYSTALLINE LESTAURIMIB ANHYDRATE AND AMORPHOUS LESTAURIMIB | ABBOTT LABORATORIES (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135401-A1 | Lestaurtinib Crystalline Form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
| US-20070135628-A1 | Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | CD2, CD22, KLRK1 | NTRK1 319/4885FLT3 107/4885JAK2 798/4885 |
| US-12527818-B2 | Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (GR) binding agents, and/or HSP90 binding agents for uses in treating cancer | HSP90AB1, HSP90B1, MAST1 | NTRK1 694/4885FLT3 759/4885JAK2 520/4885 |
| US-20080021013-A1 | JAK inhibitors for treatment of myeloproliferative disorders | JAK2, JAK3, JAK1 | NTRK1 3652/4885FLT3 17/4885JAK2 1/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1066/4885FLT3 548/4885JAK2 2701/4885 |
| US-12391946-B2 | Use of a Janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms | TERT, JAK2, MCL1 | NTRK1 2857/4885FLT3 106/4885JAK2 2/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | NTRK1 1138/4885FLT3 441/4885JAK2 2272/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | NTRK1 755/4885FLT3 159/4885JAK2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.